

SCHOLAR-IN-TRAINING AWARDS: ANNUAL MEETING

The AACR is proud to offer Scholar-in-Training Awards to enable the participation of meritorious early-career scientists at the Annual Meeting 2023. In 2023, 13 organizations or individuals generously provided the funding to support this program. The names and affiliations of the 2023 Scholar-in-Training Award recipients, along with the abstract numbers and titles of their abstracts, are listed below.

2023 AACR SCHOLAR-IN-TRAINING AWARDS SUPPORTED BY AN INDEPENDENT EDUCATIONAL GRANT FROM ABBVIE

Early career investigators who will be presenting meritorious abstracts at the AACR Annual Meeting 2023 were generously supported by an independent educational grant from AbbVie.

Mwangala Akamandisa, PhD, Perelman School of Medicine Univ. of Pennsylvania, Langhorne, PA. **1183**. Mutation type and location in breast cancer susceptibility genes are associated with differential risk in the general population.

Shankara K. Anand, MS, Broad Institute of MIT & Harvard, Cambridge, MA. **3132**. *CLUMPS-PTM*: Spatial clustering of post-translational modifications across cancer types.

Jana Biermann, PhD, Columbia University Irving Medical Center, New York, NY. **109**. Multi-modal single-cell analysis of immunotherapy-experienced cutaneous and mucosal melanoma.

Liang Chang, PhD, Broad Institute of MIT and Harvard, Cambridge, MA. **1175**. Systematic profiling of conditional pathway activation as a new class of cancer dependency.

Taek-Chin Cheong, PhD, Boston Children's Hospital and Harvard Medical School, Boston, MA. **313**. Mechanisms of oncogenic tyrosine kinase fusion formation and selection in human cancers.

Janine M. DeBlasi, MSc, Moffitt Cancer Center, Tampa, FL. **12**. Distinct Nrf2 signaling thresholds mediate lung tumor initiation and progression.

Nathaniel Deboever, MD, UT MD Anderson Cancer Center, Houston, TX. **726**. Machine learning prediction of financial toxicity in patients with resected lung cancer.

Francisco Exposito, PhD, Yale University School of Medicine, New Haven, CT. **1124**. PTEN loss confers resistance to anti-PD-1 therapy in NSCLC by increasing tumor infiltration of T regulatory cells.

Jimmy A. Guo, BA, Broad Institute of MIT and Harvard, Cambridge, MA. **5775**. GLIS3 drives a neural-like malignant state enriched after neoadjuvant treatment in pancreatic cancer.

Deli Hong, PhD, Dana-Farber Cancer Institute, Brookline, MA. **5727**. Identification of synthetic lethal vulnerabilities in cancers with loss of function mutations in NOTCH.

Lucas Zhongming Hu, PhD, Columbia University Irving Medical Center, New York, NY. **1119**. Systems pharmacology approaches to study tumor drug mechanism of action.

Kelsey E. Huntington, BS, Brown University, Providence, RI. **5636**. Multiplex digital spatial profiling (DSP) of proteins in the tumor microenvironment in response to GSK-3 inhibition by 9-ING-41 (elraglusib) correlates with novel immunostimulatory effects observed *in vivo*.

Neel Jasani, MS, Moffitt Cancer Center, Tampa, FL. **1159**. BRAF- mediated PHGDH induction establishes a metabolic vulnerability in melanoma.

Jiexi Li, MS, UT MD Anderson Cancer Center, Houston, TX. **3515**. Histone demethylase KDM5D drives sex-specific differences in colorectal cancer.

Chang-Ching Lin, PhD, UT Southwestern Medical Center, Dallas, TX. **3934**. PRMT5 is an actionable target in CDK4/6 inhibitor-resistant ER+/Rb-deficient breast cancer.

Runying Long, MS, The University of Hong Kong, Hong Kong, Hong Kong. **617**. Oncogenic CXCL10 triggers CD8⁺ T cell exhaustion in ovarian cancer.

Renyta Moses, BS, University of Pennsylvania, Philadelphia, PA. **2608**. Defining the function of tumor suppressor p53 arginine 181 residue in tumorigenesis.

Aron Onerup, MD PhD, St. Jude Children's Research Hospital, Memphis, TN. **5770**. Cardiorespiratory fitness and BMI in youth and five-year mortality after site-specific cancer in men: a population-based cohort study with register linkage.

Zahraa Rahal, MD, UT MD Anderson Cancer Center, Houston, TX. **2883**. Gut microbiome dysbiosis promotes immune suppression and lung cancer development.

Ozge Saatci, MS, The Medical University of South Carolina (MUSC), Charleston, SC. **5728**. Inhibition of TACC3 blocks the growth of highly aggressive breast cancers with centrosome amplification.

David T. Severson, MD, DPhil, Brigham and Women's Hospital, Durham, NC. **95**. Uncommitted cells and phenotypic plasticity elucidate the complexity of the epithelial-mesenchymal molecular gradient of pleural mesothelioma.

Mengyao Shi, MPH, Washington University School of Medicine, St. Louis, MO. **739**. Alcohol consumption patterns among US cancer survivors: A cross-sectional study of the All of Us Research Program.

Rebecca Simpson, BS, Melanoma Institute Australia, The University of Sydney, Sydney, Australia. **3463**. Longitudinal microbiome-immune dynamics in melanoma patients treated with immune checkpoint inhibitor immunotherapy.

Maximilian A. R. Strobl, PhD, Moffitt Cancer Center, Tampa, FL. **5694**. Adaptive treatment scheduling of PARP inhibitors in ovarian cancer: Using mathematical modeling to assess clinical feasibility and estimate potential benefits.

Ankur Tiwari, MBBS, UT Health Science Center at San Antonio, San Antonio, TX. **2679**. Combination of CDK 4/6 inhibitor palbociclib with rapamycin synergistically inhibits growth of hepatocellular carcinoma in preclinical models.

Tomotaka Ugai, MD, PhD, Brigham and Women's Hospital, Boston, MA. **5760**. Molecular, immune, and microbial profiles of early-onset, intermediate-onset, and later-onset CRCs.

Hanwen Wang, MS, Johns Hopkins University School of Medicine, Baltimore, MD. **5697**. Predicting response to PD-L1 inhibition in NSCLC using a quantitative systems pharmacology model guided by immunogenomic data.

Jaroslav Zak, DPhil, PhD, The Scripps Research Institute, La Jolla, CA. **5743**. Reprogramming myeloid cells by JAK inhibition to enhance checkpoint blockade immunotherapy.

Chao Zhang, PhD, Moffitt Cancer Center, Tampa, FL. **3465**. HDAC8 regulates immune escape in melanoma through increased transcription of inhibitory cytokines that increase accumulation of myeloid-derived suppressor cells (MDSCs).

2023 AACR-AMERICAN BRAIN TUMOR ASSOCIATION SCHOLAR-IN-TRAINING AWARDS

The American Brain Tumor Association has graciously donated funds to support young investigators who will be presenting high-quality abstracts in brain cancer research for both primary and secondary (metastatic) brain tumors at the AACR Annual Meeting 2023.

Daniel Azorín, MS, Neurology Clinic and National Center for Tumor Diseases, University Hospital Heidelberg. Clinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany. **1084**. AI-aided drug development for disconnecting glioma tumor microtubule networks.

Anne-Florence Blandin, PhD, Dana-Farber Cancer Institute, Boston, MA. **1201**. *ALK* amplification and rearrangements are recurrent targetable events in congenital and adult glioblastoma.

Syed M. Faisal, PhD, University of Michigan Medical School, Ann Arbor, MI. **5835**. Targeting discoidin domain receptor 1 (DDR1) reverses glioma immune suppression by remodeling collagen fiber architecture.

Toshiro Hara, PhD, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA. **1246**. Single-cell profiles of multiplexed *in vivo* models facilitate the characterization of phenotypic plasticity and invasion in glioblastoma.

Mariam Lotfy Khaled, PhD, H. Lee Moffitt Cancer Center, Tampa, FL. **1192**. Branched-chain keto acids exert an immune-suppressive and neurodegenerative microenvironment in CNS leptomeningeal lymphoma.

Yamhilette Licon Munoz, PhD, University of New Mexico Health Sciences Center, Albuquerque, NM. **5802**. The impact of tumor-treating fields on cancer stem-like cells isolated from the sub-ventricular zone of glioblastoma patients.

Sandhya Prabhakaran, PhD, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL. **6614**. Spatial transcriptomic driven mechanistic model to investigate and predict pathogenesis of oligodendroglioma.

Uday Pratap, PhD, UT Health Science Center at San Antonio, San Antonio, TX. **1718**. Development of potent estrogen receptor beta agonists for treating glioblastoma.

2023 AACR-BREAST CANCER RESEARCH FOUNDATION SCHOLAR-IN-TRAINING AWARDS IN MEMORY OF REBECCA SCHEINKMAN

The Breast Cancer Research Foundation has graciously donated funds to support young investigators who will be presenting high quality abstracts in breast cancer research at the AACR Annual Meeting 2023. This year, this funding has been given by the Breast Cancer Research Foundation to honor the memory of Rebecca Scheinkman.

Pin-Ji Lei, PhD, Massachusetts General Hospital, Harvard Medical School, Boston, MA. **1298**. Single cell analysis of breast cancer progression and metastasis to lymph nodes reveals cancer cell plasticity and MHC class II-mediated immune regulation.

Praful R. Nair, PhD, Johns Hopkins University, Baltimore, MD. **3608**. MLL1 regulates cytokine-driven cell migration and metastasis.

2023 AACR-BRISTOL MYERS SQUIBB SCHOLAR-IN-TRAINING AWARDS

Bristol Myers Squibb has graciously donated funds to support early career investigators who will be presenting meritorious abstracts at the AACR Annual Meeting 2023.

Majd Al Assaad, MD, New York Presbyterian Hospital Weill Cornell University Medical Center, New York, NY. **3437**. Whole genome and transcriptome sequencing of a pan cancer cohort unearths novel therapeutic avenues.

Alaina Bever, BS, Harvard T.H. Chan School of Public Health, Boston, MA. **3006**. Metabolomic signatures of metabolic disturbance and inflammation in relation to colorectal cancer risk.

Bina Desai, MS, H. Lee Moffitt Cancer Center, Tampa, FL. **552**. Stromal facilitated multifactorial resistance to tumor cells against targeted therapies in ALK+ NSCLC.

Guochong Jia, PhD, Vanderbilt University Medical Center, Nashville, TN. **1180**. Identification of target proteins for breast cancer genetic risk loci and blood risk biomarkers in a large study by integrating genomic and proteomic data.

Panagiotis Karras, PhD, VIB-KU Leuven Center for Cancer Biology, Leuven, Belgium. **103**. Dissecting cell state diversity during melanoma growth and metastasis.

Guodong Lian, MD, PhD, Columbia University Medical Center, New York, NY. **3496**. p53 mutation biases SCJ progenitor cells towards dysplasia rather than metaplasia in Barrett's esophagus.

Anjali Mittal, MS, University of Michigan, Ann Arbor, MI. **1160**. A machine learning based method for in-vivo metabolic flux analysis of patient tumors.

Béga Murray, MSc, National Cancer Inst. - Bethesda Campus, Bethesda, MD. **3563**. SWI/SNF-associated DPF1 is a unique transcriptional regulator of malignant peripheral nerve sheath tumors.

Anthony T. Nguyen, MD, PhD, Cedars-Sinai Medical Center, Los Angeles, CA. **6409**. Non-redundant mechanisms of immune resistance to radiotherapy converge on innate immunity.

Jeffrey Patterson-Fortin, MD, PhD, Dana-Farber Cancer Institute, Boston, MA. **6190**. Polymerase theta inhibition activates the cGAS-STING pathway and cooperates with immune checkpoint blockade in BRCA-deficient cancers.

Gilbert J. Rahme, PhD, Dana-Farber Cancer Institute, Boston, MA. **3479**. Modeling epigenetic lesions that cause gliomas.

Martin Rotbauer, BS, Princess Margaret Cancer Centre, Toronto, Canada. **90**. Exploring the role of common circulating tumor cell-associated genes in estrogen receptor-positive breast cancer recurrence.

Thin N. Tran, MS, Memorial Sloan Kettering Cancer Center, New York, NY. **4259**. Identification of anti-neoplastic therapy given before initial visit at a referral center using natural language processing applied to medical oncology initial consultation notes.

Danh D. Truong, PhD, UT MD Anderson Cancer Center, Houston, TX. **1196**. The epigenetic impact and therapeutic opportunity of AR-directed therapy for DSRCT.

Bogang Wu, PhD, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA. **1696**. Systematic identification of pathways associated with antibody drug conjugate sensitivity in breast cancer.

Yiming Wu, PhD, City of Hope National Medical Center, Duarte, CA. **3482**. METTL3-mediated m⁶A modification controls splicing factor abundance and contributes to CLL progression.

Xiaofei Zhi, MD, PhD, Irving Cancer Research Center, Columbia University Medical Center, New York, NY. **1193**. Sensory innervation directly promotes gastric cancer and modulates the tumor microenvironment.

2023 AACR-SCHOLAR-IN-TRAINING AWARDS SUPPORTED BY AN INDEPENDENT EDUCATIONAL GRANT FROM DAIICHI SANKYO

Early career investigators who will be presenting meritorious abstracts at the AACR Annual Meeting 2023 were generously supported by an independent educational grant from Daiichi Sankyo.

Lindsay A. Caprio, BS, Columbia University Irving Medical Center, New York, NY. **5944**. Relief of chromosomal instability-induced cGAS-STING signaling sensitizes *STK11*-mutant non-small cell lung cancer to immune checkpoint blockade.

Mohamed Gouda, MD, The University of Texas MD Anderson Cancer Center, Houston, TX. **1173**. Landscape of 4,506 pan-cancer samples harboring *BRAF*^{V600E} mutations, and *NTRK/RET* Fusions from 137,401 adult patients with cancer: Clinical implications for tissue agnostic therapies.

Christopher R. Grant, MS, University of California Irvine Medical Center, Orange, CA. **4404**. Survival impact and trends of immunotherapy use in metastatic merkel cell carcinoma in the checkpoint era: analysis of a large database.

Justin Jee, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY. **5721**. Automated annotation for large-scale clinicogenomic models of lung cancer treatment response and overall survival.

M. Haidar Kasem, MS, German Cancer Research Center, Heidelberg, Germany. **136**. Single cell lineage analysis reveals clonal evolution and dynamic intra-clonal gene expression states during colorectal cancer progression.

Sungsoo Kim, PhD, Columbia University Irving Medical Center, New York, NY. **3876**. Kinetics of RTK activation determine ERK signaling dynamics and resistance to BRAF and MEK inhibitors.

Blair V. Landon, BS, Johns Hopkins University School of Medicine, Baltimore, MD. **3374**. Circulating cell-free tumor DNA dynamics capture minimal residual disease with neoadjuvant immune checkpoint blockade plus chemoradiotherapy for patients with operable esophageal/gastroesophageal junction cancer.

Xuebing Leng, MS, MPH, University of Miami Miller School of Medicine, Miami, FL. **3807**. MicroRNA-29a synergizes with PD-1 therapy to regulate anti-tumor immunity.

Benjamin B. Morris, PhD, UT MD Anderson Cancer Center, Houston, TX. **6115**. Comprehensive DNA repair landscape analysis reveals novel small cell lung cancer biology.

Somnath Tagore, PhD, Columbia University, New York, NY. **3517**. Multi-modal single-cell and spatial genomics reveals genomic, adaptive and microenvironmental features of human non-small cell lung cancer brain metastasis.

Shengzhe Zhang, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX. **1714**. *CRACD/KIAA1211* loss drives cell plasticity and immune evasion of small cell lung cancer.

2023 AACR-DOREEN J. PUTRAH CANCER RESEARCH FOUNDATION SCHOLAR-IN-TRAINING AWARDS

These awards are presented to early career investigators of meritorious abstracts to be presented at the AACR Annual Meeting 2023. These awards are made possible through a gracious donation from the Doreen J. Putrah Cancer Research Foundation.

Ganesh Acharya, MS, Texas Tech University Health Sciences Center, Lubbock, TX. **2667**. PARG inhibition augments CHK1 inhibitor-induced replication stress and synergistically kills ovarian cancer cells.

Vincent Bernard, MD, PhD, UT MD Anderson Cancer Center, Houston, TX. **1096**. Single cell transcriptomic sequencing of pancreatic ductal adenocarcinoma reveals an enrichment of immunosuppressive pathways in patients at high risk for early local progression following stereotactic body radiation therapy.

Carla Bertulfo, MPhil, Columbia University Irving Medical Center, New York, NY. **3928**. Therapeutic targeting of NOTCH1 and neddylation pathway in T cell acute lymphoblastic leukemia.

Nilanjana Chatterjee, PhD, UCSF - University of California San Francisco, San Francisco, CA. **3878**. Targeting Hippo-YAP, BRD4 and RAS-MAPK interplay in lung cancer to forestall drug resistance.

Francesca Citron, PharmD, PhD, UT MD Anderson Cancer Center, Houston, TX. **303**. DPY30 loss leads to DNA re-replication and immunoediting in pancreatic ductal adenocarcinoma.

Guangzheng Deng, MS, The Chinese University of Hong Kong, Hong Kong, Hong Kong. **2574**. An exon-skipping HDAC1 novel isoform promotes colorectal carcinogenesis.

SeongJun (James) Han, PhD, Harvard University, Boston, MA. **5149**. Age-associated remodeling of anti-tumor T cell immunity and metabolism.

Xue-Yan He, PhD, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY. **62**. Untangling the connection between stress and metastatic breast cancer.

Yoshinobu Konishi, MD, PhD, DFCI/Harvard Medical School, Brookline, MA. **796**. Altered immune response to vaccination in patients with plasma cell premalignancy.

Felix Korell, MD, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA. **4098**. Chimeric antigen receptor (CAR) T cells overexpressing Bcl-xL increase proliferation and antitumor activity alone and in combination with BH3 mimetics.

Jens Luebeck, PhD, UC San Diego, La Jolla, CA. **3130**. Extrachromosomal DNA in the cancerous transformation of Barrett's esophagus.

Claudia Manriquez Roman, MS, Mayo Clinic, Rochester, MN. **5074**. Addition of MAPK inhibitors to prime and sensitize poorly differentiated thyroid cancers as a strategy to improve TSHR-CART cell therapy antitumor activity.

Katherine E. Masih, BS, National Institutes of Health (NIH), Bethesda, MD. **1199**. Discovery of subtype-specific and therapy associated effects on the tumor immune microenvironment in pediatric neuroblastoma.

Nicole M. Mattson, BA, Beckman Research Institute of The City of Hope, Monrovia, CA. **6234**. Targeting integrin alpha V beta 5 heterodimer stability using a novel small molecular inhibitor for tumor suppression.

Siddharth Mehra, PhD, University of Miami, Miami, FL. **653**. Tumor cell-macrophage crosstalk drives immune suppression in pancreatic cancer.

Jayanta Mondal, BE, The University of Texas MD Anderson Cancer Center, Houston, TX. **1294**. Loss of bromodomain-7 (BRD7) promotes breast cancer lung metastasis by reprogramming the tumor immune microenvironment.

Nicole Peiris, PhD, Harvard Medical School, Massachusetts General Hospital, Boston, MA. **4353**. Utilizing scRNA sequencing to understand biomarkers of response and resistance to Sacituzumab Govetican in localized TNBC.

Moez Rathore, PhD, Case Western Reserve University School of Medicine, Cleveland, OH. **3636**. Liver endothelium secreted LRG1 promotes metastatic colorectal cancer growth through the HER3/RSK/EIF4B AXIS.

David Requena, MS, Rockefeller University, New York, NY. **1516**. Bulk and spatial single-cell transcriptomic characterization of fibrolamellar hepatocellular carcinoma.

Thomas Simon, PhD, USC - University of Southern California, Los Angeles, CA. **5842**. Determining the tumor supportive and inhibitory capabilities of cancer associated fibroblast subpopulations in central nervous system metastasis.

Ian Sutton, BS, National Cancer Institute, Iowa City, IA. **2413**. Glioblastoma stem-like cells are resistant to the negative effects of increased aneuploidy on in vitro survival and radiosensitivity.

Max M. Wang, MPH, Northwestern University, Evanston, IL. **2714**. Inhibiting Myc using heterofunctional polymeric degrading chimeras (HYDRACs): a novel class of compounds capable of targeted protein degradation.

Nicholas K. Wang, MHS, UCLA - University of California Los Angeles, Los Angeles, CA. **4305**. Germline structural variants shape prostate cancer clinical and molecular evolution.

Adam C. Weiner, BS, Memorial Sloan Kettering Cancer Center, New York, NY. **3122**. Single-cell DNA replication dynamics for genomically unstable cancer cells.

Saigopalakrishna S. Yerneni, PhD, Carnegie Mellon University, Pittsburgh, PA. **836**. Enabling mRNA Medicine for Brain Tumors.

2023 AACR-JUNE L. BIEDLER SCHOLAR-IN-TRAINING AWARDS

These awards are presented to authors of meritorious abstracts to be presented at the AACR Annual Meeting 2023. These awards are made possible through the Estate of Dr. June L. Biedler. The late Dr. Biedler was a dedicated member of AACR and a distinguished scientist at Memorial Sloan Kettering Cancer Center. Dr. Biedler believed that science communication is a cornerstone to the acceleration of progress.

Delia Friel, MS, DFCI/Harvard Medical School, Boston, MA. **3875**. Evaluation of resistance mechanisms to ARV471, an ER-targeted PROTAC.

Sushanta Halder, MPharm, University of Nebraska Medical Center, Omaha, NE. **1756**. Novel first-in-class oral small molecule inhibitor EC914 overcomes docetaxel-resistance by inhibiting LIFR/c-Myc axes in CRPC.

Chendi Li, PhD, Massachusetts General Hospital, Charlestown, MA. **3868**. Aurora kinase A inhibition overcome adaptive resistance to KRAS G12C inhibitor by G1-checkpoint induced apoptosis in KRAS non-small cell lung cancer.

Pooja A. Shah, PhD, UT MD Anderson Cancer Center, Houston, TX. **2847**. Concurrent inactivation of PI3K and PLK1 is synergistic and overcomes acquired resistance to PI3K inhibitors in *NOTCH1*^{MUT}HNSCC.

David Alejandro Terrero, MD, University of Toledo, Toledo, OH. **2846**. The mitochondrial dynamics of breast cancer regulate P-glycoprotein expression.

2023 AACR-LUDWIG INSTITUTE FOR CANCER RESEARCH SCHOLAR-IN-TRAINING AWARD

These awards were funded by a generous donation from Ludwig Institute for Cancer Research to early career scientist presenting exceptional research at the AACR Annual Meeting 2023.

Jonathan M. Downie, MD, PhD, Harvard Medical School/Massachusetts General Hospital, Somerville, MA. **5247**. The effect of aspirin on the transcriptional landscape of the colon.

Alvaro Curiel Garcia, PhD, Columbia University Irving Medical Center, New York, NY. **4803**. BMAL2 is a KRAS-dependent master regulator of hypoxic response in pancreatic ductal adenocarcinoma.

Brendan T. Heiden, MD, MPHS, Washington University In St. Louis, St. Louis, MO. **734**. Comprehensive validation of high-risk clinicopathologic features in early-stage, node-negative non-small cell lung cancer.

Susana Castro Pando, BS, UT MD Anderson Cancer Center, Houston, TX. **1188**. IL-17/IL-17RA signaling in the pancreatic epithelium upregulates B7-H4 to promote tumorigenesis.

Jaime L. Schneider, MD, PhD, MGH/Harvard Medical School, Boston, MA. **1156**. GUK1 is a novel metabolic liability in oncogene-driven lung cancer.

Carli M. Stewart, BS, Mayo Clinic, Rochester, MN. **1153**. IL-4 depletion leads to the improvement of CART cell therapy.

2023 AACR-MARGARET FOTI FOUNDATION SCHOLAR-IN-TRAINING AWARDS

Through a generous gift of the Margaret Foti Foundation, these awards recognize outstanding young investigators for their meritorious work in head and neck, lung, ovarian, pancreatic, prostate, and pediatric brain cancer research.

Naheed Arfin Borah, MTech, L V Prasad Eye Institute, Bhubaneswar, India. **1200**. Aurora kinase A is a potential therapeutic target regulated by the MYCN oncogene in human retinoblastoma.

Pushpamali De Silva, PhD, Massachusetts General Hospital and Harvard Medical School, Boston, MA. **3228**. Photodynamic priming enhances immunotherapy responses overcoming oncogenic drivers in pancreatic patient derived tumor organoids.

Soma Ghosh, PhD, UT MD Anderson Cancer Center, Houston, TX. **1564**. Novel combination of TRIP13 and Aurora kinase A inhibition demonstrated extensive DNA damage and immunogenic cell death in RB-deficient cancers.

Ruida Hou, MD, University of Tennessee Health Science Center, Memphis, TN. **4923**. Prostaglandin E2 receptor EP2: A novel target for high-risk neuroblastoma.

Mohammed L. Ibrahim, PhD, H. Lee Moffitt Cancer Center, Tampa, FL. **3264**. Sotorasib, a selective G12C K-RAS inhibitor, modulates the tumor microenvironment to promote TNF α and IFN γ signaling and augment immunotherapy response.

Grégoire Marret, MD, Institut Curie, Paris, France. **3363**. Spatial and longitudinal tumor heterogeneity in head and neck squamous cell carcinoma patients treated with primary surgery.

Kinza Rizwan, PhD, Baylor College of Medicine, Houston, TX. **1705**. *SPOP*: An essential gene for normal and prostate tumor cells.

Nilesh Prakash Talele, PhD, Harvard Medical School/Massachusetts General Hospital, Norwood, MA. **4416**. IL-1 blockade prevents cardiac toxicity and improves immunotherapy efficacy.

Ignacio Vázquez-García, PhD, Memorial Sloan Kettering Cancer Center, New York, NY. **102**. Transient chromosomal instability as a driver of ovarian cancer genome evolution.

Irene Y. Xie, MD, University of Toronto, Toronto, Canada. **173**. Genomic characterization of patient-derived pancreatic cancer organoids.

Wei Zhao, MD, PhD, Henry Ford Health System, Detroit, MI. **5762**. New perspective on racial disparities in prostate cancer: Identification of new molecular subsets using whole-mount radical prostatectomy.

2023 AACR-PEZCOLLER FOUNDATION SCHOLAR-IN-TRAINING AWARDS

The Pezcoller Foundation supports these awards to enhance participation in the programs and activities of the AACR by early-career investigators residing in Europe and to provide these outstanding Scholar-in-Training Awardees with an opportunity to share their research findings with the international cancer research community at the AACR Annual Meeting.

Roberto Ferrara, MD, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. **5506**. Circulating immature neutrophils early detect hyperprogressive disease upon first-line PD-1/PD-L1 inhibitors in non-small cell lung cancer patients selecting best candidates for platinum-based chemotherapy and PD-1/PD-L1 inhibitors combinations.

Giulia Francescato, MS, Italian Institute for Genomic Medicine (IIGM), Candiolo, Italy. **3797**. Fecal miRNA profiles and gut metagenome composition in Lynch syndrome: results from a mouse model study and human subjects.

Sia V. Lindskrog, MS, Aarhus University Hospital, Aarhus N, Denmark. **5600**. Utility of circulating tumor DNA and transcriptomic profiling in predicting outcome in muscle invasive bladder cancer patients.

Alessia Potenza, PhD, IRCCS San Raffaele Scientific Institute, Milan, Italy. **902**. Harnessing CD39 for the treatment of colorectal cancer and liver metastases by engineered T cells.

Simone Weiss, MS, Aarhus University Hospital, Aarhus N, Denmark. **3778**. Genome-Scale CRISPRa and CRISPRi screening for lncRNA drivers of prostate cancer progression.

Daniel K. Zingg, PhD, Netherlands Cancer Institute, Amsterdam, Netherlands. **3488**. Truncated FGFR2 - a clinically actionable oncogene in multiple cancers.

2023 AACR-PROSTATE CANCER FOUNDATION SCHOLAR-IN-TRAINING AWARDS

The Prostate Cancer Foundation has graciously donated funds to the AACR to support early-career investigators who will be presenting meritorious abstracts in prostate cancer research at the AACR Annual Meeting 2023.

Ricardo A. Cordova, MS, Indiana University School of Medicine, Indianapolis, IN. **4818**. GCN2 eIF2 kinase and p53 coordinate amino acid homeostasis and metabolism in prostate cancer.

Chui Yan Mah, PhD, The University of Adelaide, Adelaide, Australia. **1157**. Uncovering a novel role of peroxisomal β -oxidation in advanced, treatment-resistant prostate cancer.

Jitender Monga, PhD, Henry Ford Health System, Detroit, MI. **1698**. Novel role of Tribbles 2 driving treatment-emergent neuroendocrine differentiation in prostate cancer.

Anqi Wang, MBBS, University of Southern California, Pasadena, CA. **3508**. Association between clonal hematopoiesis and risk of prostate cancer in a large sample of African ancestry men.

2023 AACR-SANOFI SCHOLAR-IN-TRAINING AWARDS

Sanofi has graciously donated funds to support early career investigators who will be presenting meritorious work in cancer research at the AACR Annual Meeting 2023.

Gelan Ayana, MS, Kumoh National Institute of Technology Education Organization, Gumi, Korea, Republic of. **5437**. Vision transformers for breast cancer human epidermal growth factor receptor 2 (HER2) expression staging without immunohistochemical (IHC) staining.

Jessica Ziyu Chen, MEng, Weill Cornell Medicine, Memorial Sloan Kettering Cancer Center, New York, NY. **5931**. Characterizing tumor heterogeneity through bulk and single cell analysis of patient derived bladder cancer models.

Arielle Elkrief, MD, Memorial Sloan Kettering Cancer Center, Montréal, Canada. **5185**. Intratumoral *Escherichia* is associated with response to single-agent immune checkpoint inhibition in patients with advanced non-small cell lung cancer.

Elshad Hasanov, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX. **5788**. Single-cell and spatial transcriptomic mapping of human renal cell carcinoma brain metastases uncovers actionable immune-resistance targets.

Jabril Johnson, PhD, Morehouse School of Medicine, Smyrna, GA. **3509**. 1,25-dihydroxyvitamin D₃-mediated suppression of genes associated with cell cycle regulation and actin organization in a non-malignant African American prostate cell line.

Aditi S. Khatpe, MS, Indiana University School of Medicine, Indianapolis, IN. **5458**. TONSL is an immortalizing oncogene of the chromosome 8q24.3 amplicon and new therapeutic target in breast cancer.

Sieun Lee, BS, Ewha Womans University, Seoul, Korea, Republic of. **5860**. ZEB1-driven reconstruction of the hyaluronan network establishes a pro-metastatic microenvironment in lung adenocarcinoma.

Jonathan T. Lei, PhD, Baylor College of Medicine, Houston, TX. **5726**. Pan-cancer proteogenomics expands the landscape of therapeutic targets.

Chang In Moon, MS, Baylor College of Medicine, Houston, TX. **5717**. Bridging the gap between clinical-omics and machine learning to improve cancer treatment.

Long Nguyen Chi, MD, PhD, University of Chicago, Chicago, IL. **4807**. BACH1 proline hydroxylation regulates the hypoxia response and metastasis in triple negative breast cancer.

Jina Park, MS, Johns Hopkins, Baltimore, MD. **6256**. Inhibition of class IIa HDACs potentiates MYC inhibitor-driven cytotoxicity by inducing MYC depletion and oxidative stress in non-small cell lung cancer.

Ajinkya Patil, MS, Dana-Farber Cancer Institute/Harvard Medical School, Brookline, MA. **3485**. Intrinsically disordered regions of the ARID1A/B tumor suppressors encode an interaction network within biomolecular condensates that directs mSWI/SNF chromatin remodeler complex activity.

Qizhi Qin, PhD, Johns Hopkins University School of Medicine, Mclean, VA. **3630**. TrkA+ sensory neurons modulate macrophage phenotype in osteosarcoma.

Biagio Ricciuti, MD, Dana-Farber Cancer Institute, Boston, MA. **6629**. Genomic and immunophenotypic landscape of acquired resistance to PD-(L)1 blockade in non-small cell lung cancer.

Alessandro Vasciaveo, PhD, Columbia University Irving Medical Center, New York, NY. **1116**. Identifying neuroendocrine prostate cancer drivers using *in vivo* forward genetics.

Haochen Zhang, BS, Memorial Sloan Kettering Cancer Center, New York, NY. **1169**. Genomic evolution of pancreatic cancer at single-cell resolution.

2023 AACR-SYGNATURE DISCOVERY SCHOLAR-IN-TRAINING AWARDS IN ASSOCIATION WITH THE CICR WORKING GROUP

Sygnature Discovery has graciously donated funds to the AACR to support an early-career investigator who will be presenting meritorious work in small molecular drug discovery research at the AACR Annual Meeting 2023.

Neelkanth M. Bardhan, PhD, Massachusetts Institute of Technology (MIT), Cambridge, MA. **820**. Photo-activatable ON-OFF microparticles for on-demand pulsatile drug delivery in a breast cancer model.

DaeYong Lee, PhD, UT MD Anderson Cancer Center, Houston, TX. **838**. Development of cationic polypeptide-based adjuvants for cancer immunotherapy.